Navigation Links
ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
Date:1/26/2009

ase Ib clinical trial with TB-403, and in assisting Roche in paving the way for the broader clinical development program with this unique anti-cancer agent."

Svein Mathisen, CEO of BioInvent, said, "We are delighted to receive the success fee associated with this important event in our key strategic alliance with Roche. A good momentum has been achieved in the collaboration, and the value of the program continues to be enhanced. TB-403 has the potential to become a significant new treatment for cancer and we are pleased to be supporting Roche in its progress towards commercialisation."

Legal disclaimer

This press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

Notes to Editors:

About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company's lead product Microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications and as a potential therapy for stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnol
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
4. PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications
5. Kiadis Pharma Receives Two Orphan Drug Designations for Reviroc(TM) From the FDA
6. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
7. PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S.
8. Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union
9. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
10. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
11. Abbott Receives Complete Response Letter From FDA for Controlled-Release Hydrocodone With Acetaminophen

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009).... 25 /PRNewswire-Asia-FirstCall/ -- China Sky One,...pany") (Nasdaq: CSKI ), a,leading fully integrate...over-the-counter drugs in the People,s Republic of...ecently passed the Chinese National Institute for,...cts ("ICPBP") examination,for two of its new produ...
(Date:11/25/2009)...Newswire/ -- Reportlinker.com announces that a new...gue: ,, Mammography Equipment - A Global Mark...m/p0164330/Mammography-Equipment---A-Global-Market...t cancer in industrialized as well as developing n... the mammography market. Globally, escalating awar...
(Date:11/25/2009)...v. 25 Swissray International, Inc....phy ( ddR ) systems, announced today that its oper...tor with a long term view towards growing Swissray... all assets and intellectual property, as well as ... and growth Swissray is now poised to move to the ...
Breaking Medicine Technology:China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8Swissray International Announces New Ownership 2AMD LASERS Announces New Partnership with Dr Larry Rosenthal and Aesthetic Advantage 6460 1AMD LASERS Announces New Partnership with Dr Larry Rosenthal and Aesthetic Advantage 6460 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 6458 1Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 6458 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 6458 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 1Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 2Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 4Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 5Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 6Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 7Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 8Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 9Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 10
(Date:11/27/2009)...7 Shamir Optical Industr...ovider of innovative products and technology to th... board of directors had declared a dividend distri...pproximately NIS 37.62 million based on the Novemb...pproximately US$ 0.609 (approximately NIS 2.3 base...
(Date:11/27/2009)...rade; announced today that Spectrum Health (Grand ...prise orthopedic templating solution and its Traum... (PRWEB) November 27, 2009 -- Voyant Health...d Rapids, Michigan) has licensed its TraumaCad Ent...umaCad Extend workflow solution, to allow its orth...
(Date:11/26/2009)...RNewswire/ -- The diabetes population in the Unite... and annual medical spending on the disease is pro...oday, according to a study published in the Decemb...ng Diabetes ® Program (NCDP), a program of No...om the University of Chicago. ,, According to t...
(Date:11/26/2009)... from the North Pole, Textsanta.net lets parents s..., North Pole, AK (PRWEB) -...s at the North Pole Santa Claus has added SMS text...e informed of his Christmas progress at the North ...nt have identified a large and growing percentage ...
(Date:11/25/2009)...wire-USNewswire/ -- When most people hear the acro...practor can also give patients the help they need....ch is where your jaw (mandible) contacts/connects ...ommon symptoms associated with TMJ dysfunction are.... But many other symptoms can be caused from TMJ ...
Breaking Medicine News(10 mins):Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2
...inois have found that a molecular pathway known to...humans is also critical to the pathology// of skel...d to advances in the palliative care of companion ...e of an enzyme, receptor activator of nuclear fact...
... not linked to a cluster of cases in Clendon, Sout...been treated for typhoid in Porirua and those case...edical officer of health, regional public health, ... the cases were in late January and one was early ...
...ies is expected to aid in longevity of life. This ...e Zutphen Study.// According to this study, a ...ular deaths and increase the life span in middle a...n body. This research studied the pattern of a...
... of losing weight. Belgium’s Janssen Animal Health...gs shed the flab.// The drug works by blocking...eat into their bloodstream. It does not affect t...y to beg for its favorite snack. Studies acros...
...nted by Finance minister P.Chidambaram has drawn c...his introductory remarks he// said: 'The education...funds. In 2007-08, I propose to enhance the alloca...ng has been a high priority and smokers have alway...
...ssue of the journal SLEEP finds that people with o... for cardiovascular disease.// The study att...ascular disease to heightened recognition and a ri... "There is abundant physiologic evidence imp...
Other Medicine News:Health News:Insights into Osteosarcoma in Cats and Dogs may Improve Palliative Care 2Health News:Union Budget: Impact on Health Sector 2Health News:Union Budget: Impact on Health Sector 3Health News:Sleep Well, Have a Healthy Heart ! 2
The Closer
5.2F Supertorque Plus
Torcon NB Advantage
8F Standard
Medicine Products: